Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of bevirimat (MPC-4326) in HIV-1 infection
ACTRN12608000258358Phase 2Active, not recruiting
- Sponsor
- Myrexis, Inc.
- Start
- Apr 2008
- Modality
- Classical Binding Small Molecules → Small Molecules
- Countries
- 4
01
Overview
Phase 2, open-label trial of bevirimat in Human immunodeficiency virus infection type 1 (2 arms), sponsored by Myrexis, Inc. Primary endpoint: Antiretroviral activity and safety through 14 days of monotherapy. Started Apr 2008; status: active, not recruiting.
02
Drugs
bevirimat
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on ACTRN12608000258358.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12608000258358.